Allopathic Medicine Manufacturing Biz For Sale In Solapur
Email
Phone
Google
LinkedIn
Facebook
About Business
The company is engaged in the production of allopathic medicine in the form of tablets and syrups. Their 39 formulations are manufactured at the premise as well as out sourced to third-party manufacturers to meet the demands.
Clientele type
The company's products are distributed through an extensive network of wholesalers and retailers operating in Solapur, Osmanabad, Latur, Beed, Parbhani, and Ahmednagar districts. Over the course of the past 40 years, our products have gained significant goodwill and trust among renowned doctors in these regions. This longstanding relationship with healthcare professionals further strengthens the reputation and reliability of our products in the market.
Premises
Our manufacturing unit is located in Solapur, Maharashtra, and occupies a total area of 14,000 square feet. Within this space, we have constructed a manufacturing unit spanning 7,000 square feet. We have secured a lease for a remarkable duration of 90 years for these premises. The annual rent for the land ranges from INR 8,000 to INR 9,000. The premises itself is a ground plus one structure, with a total plot area of 6,930 square feet and a built-up area of 6,310 square feet. This well-equipped facility accommodates various sections, including liquid oral, tablet, capsule, raw material, quality control, and microbiology. In terms of utilities, water supply is sourced from the Solapur Municipal Corporation, while electricity is provided by MSEB through a 35 HP connection. Furthermore, there is an exciting opportunity for future expansion, as adjacent land is available for purchase at an additional cost. This land, with a plot area of 12,000 square feet and a built-up area of 3,600 square feet (1+1 floors RCC construction), holds a clean title and is owned within the family. This additional space can facilitate the growth and development of operations in the future.
Asking Price Includes
Complete business setup including land and licenses.
Reason
The promoter is looking to retire
More Details
The company is proud to announce that it has obtained FDA approval for over 40 exceptional products. However, in light of the current sluggish market conditions, the decision has been made to renew the licenses for only 6 to 7 medicines at this time.
The manufacturing capabilities of the company encompass a wide range of medications, including painkillers, antibiotics, and anti-cold tablets. Within its state-of-the-art manufacturing unit, the company possesses all the necessary machinery and approved sections, ensuring top-notch production quality. These sections consist of the Tablet Section, Liquid Oral Section, Capsule Section, Quality Control (Chemical & Instrumentation), and Microbiology Section.
It is worth noting that the company's manufacturing operations experienced a temporary halt on March 25, 2020, in compliance with lockdown measures. To maintain the validity of its licenses, the company proceeded to renew the manufacturing license for a select number of essential products. As for the remaining items, the company has decided to entrust their production to reliable third-party manufacturing partners. This strategic collaboration ensures the company's ability to meet market demand effectively. However, it should be noted that these surrendered products can be reinstated for in-house manufacturing during the renewal process.
The current manufacturing licenses held by the company are valid until March 31, 2024. This includes the C, C1, and other than C, C1 licenses, all of which are eligible for renewal. The company remains committed to maintaining regulatory compliance and providing high-quality medications to serve the needs of its valued customers.
Keywords
Business Tags
₹10 to ₹200 Cr
Complete Investment Banking Solution in 120 Days
Seamless Fundraising/M&A transactions
Start your growth journey with our 25+ Years of Experienced Professional Team.
Contact IBGrid Team
